Lymphoma, B-Cell, Marginal Zone: all 428 studies
Page 3 of 5. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.
- Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT00288067Phase 1/2Results posted
- Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's LymphomaCompletedNCT00278408Phase 3Results posted
- Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's LymphomaCompletedNCT00253630Phase 2Results posted
- Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin LymphomaCompletedNCT00244855Phase 2Results posted
- Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT LymphomaCompletedNCT00210353Phase 3Results posted
- Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00119392Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
- Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's LymphomaCompletedNCT00117156Phase 2Results posted
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
- MDX-010 in Treating Patients With Recurrent or Refractory LymphomaTerminatedNCT00089076Phase 1/2Results posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's LymphomaTerminatedNCT00088881Phase 2Results posted
- Tipifarnib in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00082888Phase 2Results posted
- Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073918Phase 2Results posted
- Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
- Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin LymphomaCompletedNCT00054639Phase 2Results posted
- Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
- Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
- Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaTerminatedNCT00012298Phase 1/2Results posted
- Liso-Cel in Relapsed/Refractory Marginal Zone LymphomaActive, not recruitingNCT07777120
- Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZLActive, not recruitingNCT07480863Phase 2
- Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)Active, not recruitingNCT07387471Phase 2
- Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaActive, not recruitingNCT07247383Phase 2
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's LymphomaActive, not recruitingNCT06667687Phase 1
- Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active, not recruitingNCT06647732Phase 2
- 64Cu-LLP2A for Imaging Hematologic MalignanciesTerminatedNCT06636175Early Phase 1
- Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT LymphomaActive, not recruitingNCT06583837Phase 2
- A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin LymphomaTerminatedNCT06561425Phase 1/2
- BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.Active, not recruitingNCT06424379
- Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomasActive, not recruitingNCT06300528Phase 2
- Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)Active, not recruitingNCT06285422Phase 1
- [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone LymphomaTerminatedNCT06125028Phase 3
- Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)Active, not recruitingNCT05878184Phase 1
- A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell MalignanciesTerminatedNCT05828589Phase 1
- Glofit and Obin in Follicular Lymphoma and Marginal Zone LymphomaActive, not recruitingNCT05783596Phase 2
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesActive, not recruitingNCT05753501Phase 1
- Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaActive, not recruitingNCT05734495Phase 2
- A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
- ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesCompletedNCT05653271Phase 1
- A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesTerminatedNCT05336409Phase 1
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
- ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingNCT05025800Phase 1/2
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedNCT05024045Phase 1
- PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell MalignanciesStatus unknownNCT05003141Phase 1
- CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHLWithdrawnNCT04995536Phase 1
- B-cell Chronic Lymphoid Malignancies MarkersStatus unknownNCT04952974
- Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T CellsActive, not recruitingNCT04911478
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaTerminatedNCT04903197Phase 1
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Phase 2
- Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin LymphomaWithdrawnNCT04836832Phase 1
- Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaActive, not recruitingNCT04799275Phase 2/3
- To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)WithdrawnNCT04796922Phase 3
- Study of Acalabrutinib and Tafasitamab in MZL PatientsActive, not recruitingNCT04646395Phase 2
- Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaWithdrawnNCT04635683Phase 1
- Lenalidomide and Low-dose Cyclophosphamide for MALT LymphomaStatus unknownNCT04604028Phase 2
- CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
- Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)Active, not recruitingNCT04542824Phase 1/2
- Long-term Follow-up Study for Patients Treated With CLBR001 CAR-TCompletedNCT04488354Phase 1
- 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell CancersActive, not recruitingNCT04464200Phase 1
- An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentActive, not recruitingNCT04447716Phase 1
- VR-CAP in the First-line Treatment for Patients With Marginal Zone LymphomaCompletedNCT04433156Phase 2
- Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) LymphomaStatus unknownNCT04431089Phase 2
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone LymphomaActive, not recruitingNCT04416451Phase 2
- FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic RoleActive, not recruitingNCT04333524
- IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone LymphomaCompletedNCT04298879Phase 2
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruitingNCT04245839Phase 2
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaActive, not recruitingNCT04212013Phase 3
- Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
- A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin LymphomaTerminatedNCT04082936Phase 1/2
- ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
- BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)CompletedNCT04018248Phase 1
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingNCT03888105Phase 2
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
- A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Phase 2
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedNCT03740529Phase 1/2
- MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasActive, not recruitingNCT03697512Phase 2
- AEDV Registry of Primary Cutaneous LymphomaStatus unknownNCT03646422
- First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell LymphomaActive, not recruitingNCT03625037Phase 1/2
- A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLTerminatedNCT03547115Phase 1
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1
- Copanlisib and Rituximab in Marginal Zone Lymphoma PatientsActive, not recruitingNCT03474744Phase 2
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- Obinutuzumab in Marginal Zone LymphomaActive, not recruitingNCT03322865Phase 2
- Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2
- Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0Status unknownNCT03265158
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaActive, not recruitingNCT03147885Phase 1/2
- Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaTerminatedNCT03093831Phase 2
- Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
- Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone LymphomaCompletedNCT03031483Phase 2
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Haploidentical BMT With Post-Transplant Cyclophosphamide and BendamustineCompletedNCT02996773Phase 1
- Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02992522Phase 1
- Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT LymphomaStatus unknownNCT02987127